Here are seven main topics they healthcare executives to keep an eye out for:’ ’2016 was not a banner year for Alzheimer’ ’s drugs in development .There were four flops , including a key    trial for solanezumab , which came out of research on the " amyloid hypothesis , " or the idea that targeting beta amyloid deposits in the brain to clear them out was the way to go about treating the disease.’"